Foreign and financial buyers clear the Swiss mid-market
The ValIndex Swiss Deal Count, our weekly tally of M&A-relevant commercial-register filings, reached 120 in the week of 15 to 19 June 2026, up 40% from 86 the prior week. Press-reported deals doubled to 10 from 5.
In a single week, three foreign and financial buyers closed Swiss acquisitions across three asset classes: US-listed TTM Technologies bought PCB maker STG from its PE owner Afinum; Morocco's Laprophan took control of Ticino generics maker Rivopharm (~US$100M revenue) from its founder; and Geneva's Pictet bought the 266-room Zurich Marriott.
Swiss public buyers were active too: ORS Service AG won a CHF 47.9M social-services contract and Schneider Stahlbau a CHF 15.3M SBB rail-infrastructure award, the week's largest procurement prints. (Swiss venture funding was quiet; the eye-catching European rounds reported this week were French, not Swiss.)
Most weeks, Swiss deal flow is about who is under pressure. This week it was about who is buying. Four acquirers closed Swiss deals in five days: a Nasdaq chipmaker, a Moroccan pharma group, a Geneva private bank and a global PE firm. Different assets, one idea: the Swiss mid-market is available, right now, at a knowable price.
Our Deal of the Week is the clearest read. TTM Technologies bought STG Swiss Technology Group, the Kussnacht maker GS Swiss PCB, from PE owner Afinum, all-cash, for its first European plant. STG is a roughly CHF 40-million specialist in circuits for surgical robots, hearing aids and defence: hard to qualify, hard to replace, the kind of asset a strategic buys rather than builds. Afinum's clean exit just gave every owner of a similar Swiss business a fresher number to anchor on.
The others rhyme. Morocco's Laprophan took control of Ticino generics maker Rivopharm from its founder, a textbook succession. Geneva's Pictet bought the Zurich Marriott outright. Cathay Capital made Geneva software firm Equadis its European platform. Three of four buyers were foreign or financial; two of four assets left a founder or a fund. When demand is that broad across electronics, pharma, real estate and software, an owner's question shifts from finding a buyer to knowing what they are worth before someone else sets the price.
We are watching whether Afinum's exit pulls more PE owners of Swiss manufacturers to market, and whether more founder-owned pharma follows Rivopharm across the border. Both tend to surface in the register first.
One Story Deeper: Ferrum moves CHF 29 million into a holding, for nothing
The register's quietest print this week may be its most telling. On 17 June, Ferrum AG of Schafisheim, the Aargau centrifuge and canning-technology maker, moved CHF 29.4 million of assets, against CHF 12 million of debt, into a holding company, Febuki Holding AG in Aarau, for no consideration. A transfer into a holding at no price is not a sale. It is the kind of structural step that often comes before a succession, a carve-out or a change of ownership, well before any of it is public.
The Tape — 6 transactions
Jun 17 PRESS | TTM Technologies, Inc. ← STG Swiss Technology Group AGSZ Deal of the Week. Nasdaq-listed TTM Technologies acquires STG (operating core GS Swiss PCB, Kussnacht am Rigi) from PE owner Afinum, all-cash, closing Q3 2026. STG makes miniaturised rigid and flex PCBs for surgical robotics, hearing aids, implantables and defence; roughly CHF 40 million revenue, 170 to 200 staff. TTM's first European plant, bought alongside ILFA GmbH of Hannover. Undisclosed (all-cash) |
Jun 17 PRESS | Laprophan Group ← Rivopharm SATI Casablanca pharma group Laprophan, through its European platform Europhan, took a controlling stake in Rivopharm SA, the Manno (Ticino) generics and CDMO maker: roughly US$100M revenue, 125 molecules, 1,500 references in 30-plus countries, with FDA-, EU- and Swissmedic-approved manufacturing. Founder Piero Poli (owner since 2005) keeps a minority. Laprophan's first European acquisition, a cross-border succession exit for a mid-cap Swiss pharma. Undisclosed (controlling stake) |
Jun 18 PRESS | Pictet Alternative Advisors ← Zurich Marriott HotelZH Pictet Alternative Advisors, the alternatives arm of Geneva's Banque Pictet, bought the 266-room, five-star Zurich Marriott on the Limmat through its Elevation II real-estate fund with operating partner Vertell. The deal is closed and Marriott stays on as operator. A Swiss private bank putting balance-sheet capital into supply-constrained downtown-Zurich hospitality. Price and seller undisclosed. Undisclosed |
Jun 16 PRESS | Cathay Capital ← Equadis SAGE Global PE firm Cathay Capital took a majority stake in Equadis, the Carouge (Geneva) product-information-management SaaS platform: about 100 staff and 600-plus customers including Procter & Gamble, Unilever and Nestle. Management reinvests and a new CEO, Pascal Laik, steps in. A capital-light Swiss software platform set up for a European buy-and-build. Terms undisclosed. Undisclosed (majority stake) |
Jun 19 REG | Maya Management SA ← OURSOLUTIONS SAGE The week's largest register-only merger, and it is a property play: Geneva real-estate firm Maya Management absorbed fellow Geneva property company OURSOLUTIONS SA (roughly CHF 33.6M net assets), filed 19 June, dated 11 May. A consolidation of Geneva real-estate holdings, with no press coverage. CHF 38.4M (net assets) |
Jun 19 REG | Bad Rheinfelden AG ← Parkresort Rheinfelden Holding AGAG Bad Rheinfelden AG, the operating company behind the Aargau thermal-spa resort, absorbed its own parent, Parkresort Rheinfelden Holding AG (roughly CHF 11.5M net assets), filed 19 June, dated 15 June. A structural simplification that folds the holding into the operating business. CHF 32.4M (net assets) |
Unlock the signals — free
Pre-deal signals scored before the press, federal procurement prints, the forward court calendar and buyable estates. Free, every Friday.
Free weekly newsletter. Unsubscribe anytime.
Based on 5,624 SOGC/SHAB publications processed this week. M&A data sourced from Swiss commercial registry filings (120 SOGC), press-reported transactions via web intelligence (10 EXA), and startup funding from Startupticker, Tech.eu, and company disclosures (10 rounds). Company distress scoring based on proprietary multi-signal model across 113,000 Swiss companies. Valuation benchmarks supplemented from Deloitte Swiss M&A reports and Dealsuite DACH data.
ValIndex scores every Swiss merger, capital move, board change and distress signal as it hits the register, and links each one to the company, its owners and its succession risk. This edition's deals and signals are all live on the platform. Request access →